Pancreatic Cancer Research

ResearcherNational Yang Ming Chiao Tung UniversityActive in the last 2 years

Chung‐Pin Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2123-8264; OpenAlex author ID A5042673919. Sources: ClinicalTrials.gov.

Their work

Papers
43 (first author 6, last author 6)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
114
Papers, trials and grants by year

2005: 1 trial · 2006: none · 2007: none · 2008: none · 2009: none · 2010: none · 2011: none · 2012: none · 2013: 1 paper · 2014: none · 2015: 1 paper · 2016: 2 papers · 2017: 1 paper · 2018: 2 papers · 2019: 1 paper · 2020: 4 papers · 2021: 3 papers · 2022: 9 papers · 2023: 5 papers · 2024: 4 papers · 2025: 1 paper · 2026: 9 papers

Papers 43

  1. SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TCOG T5217). Co-author DOI 10.1016/j.ejca.2026.116229↗
  2. Concurrent Systemic Therapy Intensity and Metabolic Response in Carbon-Ion Radiation Therapy for Locally Advanced Pancreatic Cancer. Co-author DOI 10.1016/j.ijrobp.2026.09.005↗
  3. Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcinoma: A retrospective multi-center cohort. First author DOI 10.1016/j.jfma.2026.04.039↗
  4. Response to Comment on "Optimal initial relative dose intensity of modified FOLFIRINOX in pancreatic ductal adenocarcinoma: A retrospective multi-center cohort… First author DOI 10.1016/j.jfma.2026.05.008↗
  5. Carbon ion therapy for pancreatic cancer with risk-adapted dose escalation: initial clinical experience. Co-author DOI 10.1016/j.radonc.2025.111238↗
  6. Comprehensive review of current management and precision medicine in pancreatic cancer. Last author DOI 10.1097/jcma.0000000000001365↗
  7. Effects of Auricular Acupressure on Fatigue, Sleep Quality, Physical Activity, and Quality of Life in Pancreatic Cancer Patients Undergoing Chemotherapy: A Ran… Co-author DOI 10.1097/ncc.0000000000001498↗
  8. Effects of Auricular Acupressure on Fatigue, Sleep Quality, Physical Activity, and Quality of Life in Pancreatic Cancer Patients Undergoing Chemotherapy: A Ran… Co-author DOI 10.1097/ncc.0000000000001518↗
  9. NALIRIFOX versus liposomal irinotecan plus fluorouracil/leucovorin as the second-line chemotherapy in gemcitabine refractory pancreatic adenocarcinoma: a real-… Co-author DOI 10.1177/17588359261431386↗
  10. Treatment rechallenge is safe and leads to better survival in pancreatic cancer patients with interstitial pneumonitis. Last author DOI 10.1186/s12885-025-13896-5↗
  11. Extracellular Vesicular Analysis of Glypican 1 mRNA and Protein for Pancreatic Cancer Diagnosis and Prognosis. Co-author DOI 10.1002/advs.202306373↗
  12. Systemic treatments in pancreatic cancer: Taiwan pancreas society recommendation. Co-author DOI 10.1016/j.bj.2023.100696↗
  13. Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer. Co-author DOI 10.1016/j.pan.2024.03.014↗
  14. Feasibility estimation of injected hydrodissection before definitive radiotherapy of pancreatic adenocarcinoma. Co-author DOI 10.1097/jcma.0000000000001084↗
  15. Efficacy and safety of abemaciclib alone and with PI3K/mTOR inhibitor LY3023414 or galunisertib versus chemotherapy in previously treated metastatic pancreatic… Co-author DOI 10.1002/cam4.6621↗
  16. Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adapti… Co-author DOI 10.1016/j.eclinm.2023.101897↗
  17. Carbohydrate Antigen 19-9 Response to Initial Adjuvant Chemotherapy Predicts Survival and Failure Pattern of Resected Pancreatic Adenocarcinoma but Not Which P… Co-author DOI 10.1016/j.ijrobp.2023.02.061↗
  18. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. Co-author DOI 10.1200/jco.22.01134↗
  19. Real-World Data Validation of NAPOLI-1 Nomogram for the Prediction of Overall Survival in Metastatic Pancreatic Cancer. Co-author DOI 10.3390/cancers15041008↗
  20. Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovo… Co-author DOI 10.1002/jhbp.1128↗
  21. Correlation between drug sensitivity profiles of circulating tumour cell-derived organoids and clinical treatment response in patients with pancreatic ductal a… Co-author DOI 10.1016/j.ejca.2022.01.030↗
  22. A prospective phase II study of biweekly S-1, leucovorin, and gemcitabine in elderly patients with locally advanced or metastatic pancreatic adenocarcinoma - T… First author DOI 10.1016/j.ejca.2022.06.043↗
  23. A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative On… Co-author DOI 10.1038/s41416-021-01649-7↗
  24. Nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy: A real-world experience. Last author DOI 10.1097/jcma.0000000000000650↗
  25. Dosing Pattern and Early Cumulative Dose of Liposomal Irinotecan in Metastatic Pancreatic Cancer: A Real-World Multicenter Study. Co-author DOI 10.3389/fonc.2022.800842↗
  26. The impact of spleen volume on the survival of metastatic pancreatic adenocarcinoma patients receiving nanoliposomal irinotecan. Co-author PMID 35530292↗
  27. Predictive value of albumin combined with neutrophil-to-lymphocyte ratio for efficacy and safety profiles in patients with pancreatic ductal adenocarcinoma rec… Co-author PMID 36225629↗
  28. The impact of starting dose with or without subsequent dose escalation of liposomal irinotecan on treatment outcomes in patients with metastatic pancreatic duc… Co-author PMID 36504882↗
  29. The clinical significance of esophagogastric varices in patients with advanced pancreatic cancer. Co-author DOI 10.1097/jcma.0000000000000609↗
  30. Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients' experience within a population-based study. Co-author DOI 10.1177/17588359211058255↗
  31. Evaluation of Minimal Important Difference and Responder Definition in the EORTC QLQ-PAN26 Module for Assessing Health-Related Quality of Life in Patients with… Co-author DOI 10.1245/s10434-021-09816-z↗
  32. Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPO… Co-author DOI 10.1097/mpa.0000000000001455↗
  33. Landscape of Health-Related Quality of Life in Patients With Early-Stage Pancreatic Cancer Receiving Adjuvant or Neoadjuvant Chemotherapy: A Systematic Literat… Co-author DOI 10.1097/mpa.0000000000001507↗
  34. Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study. First author DOI 10.1111/cas.14264↗
  35. Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcin… Co-author DOI 10.1200/jco.20.00590↗
  36. Endothelial-mesenchymal transition harnesses HSP90α-secreting M2-macrophages to exacerbate pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13045-019-0826-2↗
  37. Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase… Co-author DOI 10.1007/s10637-018-0580-2↗
  38. Myeloid-derived macrophages and secreted HSP90α induce pancreatic ductal adenocarcinoma development. Co-author DOI 10.1080/2162402x.2018.1424612↗
  39. Fibroblast activation protein augments progression and metastasis of pancreatic ductal adenocarcinoma. First author DOI 10.1172/jci.insight.92232↗
  40. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, rand… First author DOI 10.1016/s0140-6736(15)00986-1↗
  41. How different is the care of terminal pancreatic cancer patients in inpatient palliative care units and acute hospital wards? A nationwide population-based stu… Last author DOI 10.1186/s12904-016-0075-x↗
  42. Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial. Last author DOI 10.18632/oncotarget.4216↗
  43. A randomized controlled trial of gemcitabine plus cisplatin versus gemcitabine alone in the treatment of metastatic pancreatic cancer. Last author DOI 10.1007/s00280-013-2239-1↗

Trials 1

  1. The Role of EGFR Mutations in Pancreatic Cancer Patients Receiving Gemcitabine With or Without Erlotinib Principal investigator NCT01608841↗

Closest collaborators

The 25 strongest of 114 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Nai‐Jung Chiang · 15 shared papers, 2021–2026 · strength 2.54
  2. Li‐Yuan Bai · 13 shared papers, 2021–2026 · strength 2.14
  3. Yung‐Yeh Su · 12 shared papers, 2021–2026 · strength 2.02
  4. Yan‐Shen Shan · 14 shared papers, 2020–2026 · strength 2.01
  5. Tai‐Jan Chiu · 12 shared papers, 2021–2026 · strength 2.00
  6. Li‐Tzong Chen · 14 shared papers, 2018–2026 · strength 1.92
  7. Jen‐Shi Chen · 13 shared papers, 2020–2026 · strength 1.91
  8. Shih‐Hung Yang · 12 shared papers, 2021–2026 · strength 1.89
  9. Wen‐Chi Chou · 11 shared papers, 2021–2026 · strength 1.75
  10. Hung-Yuan Yu · 5 shared papers, 2022–2026 · strength 1.44
  11. Yen‐Yang Chen · 10 shared papers, 2021–2024 · strength 1.39
  12. Yee Chao · 7 shared papers, 1 shared trial, 2005–2026 · strength 1.31
  13. Cheng‐Ming Peng · 8 shared papers, 2021–2024 · strength 1.06
  14. I‐Wei Ho · 4 shared papers, 2026 · strength 1.01
  15. Kuei‐Chuan Lee · 3 shared papers, 2026 · strength 0.90
  16. Yuan‐Hung Wu · 4 shared papers, 2022–2026 · strength 0.79
  17. Yi‐Ming Shyr · 5 shared papers, 2015–2026 · strength 0.72
  18. Keng-Li Lan · 3 shared papers, 2024–2026 · strength 0.68
  19. Tse‐Hung Huang · 2 shared papers, 2026 · strength 0.63
  20. Do‐Youn Oh · 5 shared papers, 2020–2023 · strength 0.54
  21. Hsiu-Tzu Wang · 2 shared papers, 2026 · strength 0.50
  22. I‐Chun Lai · 2 shared papers, 2026 · strength 0.49
  23. Teresa Mercade Macarulla · 5 shared papers, 2018–2021 · strength 0.47
  24. Yu‐Wen Hu · 2 shared papers, 2024–2026 · strength 0.42
  25. Michele Reni · 3 shared papers, 2020–2023 · strength 0.36

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.